What is the 13F Pro Quality Score for HYPR?

13F Pro ranks Hyperfine, Inc. (HYPR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View HYPR's current score at https://13fpro.ai/research/HYPR (free sign-up required for the full ranking).

Where does 13F Pro source HYPR data?

All Hyperfine, Inc. fundamentals and ownership data come directly from SEC EDGAR. Hyperfine, Inc. files with the SEC under CIK 1833769. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is HYPR in?

Hyperfine, Inc. (HYPR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is HYPR research updated on 13F Pro?

HYPR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Hyperfine, Inc.(HYPR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1833769 HYPR stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $13.6M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

HYPR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Hyperfine, Inc. (HYPR), a Healthcare sector company. HYPR is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $13.6m in revenue. Based on the latest XBRL financial filings (Q1 2026), Hyperfine, Inc. reports quarterly revenue of $3.9M, net income of $-8.6M, free cash flow of $-9.3M. Top institutional holders of HYPR by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, Fosun International Ltd, Catalio Capital Management,, based on the most recent SEC filings. HYPR trades on the Nasdaq exchange and files with the SEC under CIK 1833769. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HYPR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Hyperfine, Inc. directly from SEC EDGAR. Hyperfine, Inc.'s 13F Pro composite quality score has ranged between 22 and 29 since 2022, currently 25.4 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

Revenue

Q1 2026

$3.9M

Net Income

Q1 2026

$-8.6M

Free Cash Flow

Q1 2026

$-9.3M

D/E Ratio

Q1 2026

0.38

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+5.2% YoY

$13.6MFY 2025

FY22 $6.8MFY23 $11.0MFY24 $12.9MFY25 $13.6M

Net Income

+12.6% YoY

$-35.6MFY 2025

FY22 $-44.2MFY23 $-44.2MFY24 $-40.7MFY25 $-35.6M

Operating Income

+14.2% YoY

$-37.1MFY 2025

FY22 $-73.9MFY23 $-48.1MFY24 $-43.2MFY25 $-37.1M

EPS (Diluted)

+23.2% YoY

$-0.43FY 2025

FY22 $-1.04FY23 $-0.62FY24 $-0.56FY25 $-0.43

Total Assets

-6.2% YoY

$55.3MFY 2025

FY22 $134.1MFY23 $94.2MFY24 $58.9MFY25 $55.3M

Total Debt

$0.00FY 2025

FY22 —FY23 —FY24 —FY25 $0.00

Op. Cash Flow

+27.9% YoY

$-27.9MFY 2025

FY22 $-72.3MFY23 $-41.8MFY24 $-38.8MFY25 $-27.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$13.6M +5.2%	$12.9M +16.8%	$11.0M +61.9%	$6.8M +355.5%	$1.5M +408.8%	$294.0K
Net Income	$-35.6M +12.6%	$-40.7M +8.0%	$-44.2M +0.0%	$-44.2M +31.8%	$-64.9M -176.8%	$-23.4M
Operating Income	$-37.1M +14.2%	$-43.2M +10.2%	$-48.1M +34.9%	$-73.9M -13.9%	$-64.9M -176.1%	$-23.5M
EPS (Diluted)	$-0.43 +23.2%	$-0.56 +9.7%	$-0.62 +40.4%	$-1.04 +94.1%	$-17.57	—
Total Assets	$55.3M -6.2%	$58.9M -37.5%	$94.2M -29.7%	$134.1M -33.8%	$202.5M +183.1%	$71.5M
Total Debt	$0.00	—	—	—	—	—
Operating Cash Flow	$-27.9M +27.9%	$-38.8M +7.3%	$-41.8M +42.2%	$-72.3M -53.3%	$-47.2M -119.2%	$-21.5M

AI Insight: HYPR Financial Trends

Hyperfine remains deeply unprofitable with minimal revenue, though Q4 2025 showed marginal operating-loss improvement before Q1 2026 deterioration.

• Operating loss narrowed from $11M (Q2–Q4 2024) to $8M–$9M (Q1 2026), but still unsustainable against $4M–$5M quarterly revenue.

• Operating cash burn improved to $5M in Q4 2025 from $9M average in 2024, then reverted to $9M in Q1 2026.

• Equity declined 49% from $67M (Q2 2024) to $34M (Q1 2026), with debt first appearing at $13M in Q1 2026.

⚠ Revenue flat to declining ($2M–$5M range); no clear growth trajectory to offset operating losses.

⚠ Debt introduced in Q1 2026 ($13M) while equity erodes; balance-sheet stress mounting as cash depletes.

⚠ Q4 2025 improvement in op cash burn ($5M) did not persist; Q1 2026 reverted to $9M outflow.

AI Insight: HYPR Ratio Trends

Hyperfine remains deeply unprofitable across all return metrics, with operating margin deteriorating to -144.9% in Q4 2025 before partial recovery in Q1 2026.

• Operating margin collapsed to -144.9% in Q4 2025, representing the worst quarterly result in the dataset before improving to unmeasurable levels in Q1 2026.

• ROE worsened from -60.9% in Q2 2024 to -164.0% in Q3 2025, indicating accelerating shareholder value destruction through the period.

• Debt-to-equity ratio stable at 0.38 in TTM and Q1 2026, showing moderate leverage despite persistent operating losses.

⚠ Q3 2025 ROE hit -164.0%, the nadir in the dataset. Monitor whether Q4–Q1 2026 stabilization reflects operational improvements or one-time adjustments.

⚠ All profitability and return metrics remain deeply negative. Path to positive ROIC/ROE critical to long-term viability.

Get alerted when HYPR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Hyperfine, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of HYPR

VANGUARD CAPITAL MANAGEMENT LLC
$3.7M3,453,163 sh
Fosun International Ltd
$1.9M1,742,020 sh
Catalio Capital Management, LP
$1.4M1,320,041 sh
Sio Capital Management, LLC
$1.1M1,000,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.0M955,260 sh
Alphabet Inc.
$970.6K898,720 sh
RENAISSANCE TECHNOLOGIES LLC
$788.7K730,233 sh
BlackRock, Inc.
$620.9K574,903 sh
VANGUARD FIDUCIARY TRUST CO
$568.8K526,706 sh
STATE STREET CORP
$350.0K324,070 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$3.7M	3,453,163
Fosun International Ltd	$1.9M	1,742,020
Catalio Capital Management, LP	$1.4M	1,320,041
Sio Capital Management, LLC	$1.1M	1,000,000
GEODE CAPITAL MANAGEMENT, LLC	$1.0M	955,260
Alphabet Inc.	$970.6K	898,720
RENAISSANCE TECHNOLOGIES LLC	$788.7K	730,233
BlackRock, Inc.	$620.9K	574,903
VANGUARD FIDUCIARY TRUST CO	$568.8K	526,706
STATE STREET CORP	$350.0K	324,070

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put HYPR on your watchlist

Track score changes the day Hyperfine, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is HYPR a good stock to buy?

13F Pro's AI-powered analysis of Hyperfine, Inc. (HYPR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HYPR are available on the HYPR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own HYPR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HYPR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Hyperfine, Inc.'s investment landscape.